Position: Home > News > Company News Company News

Sino Biopharm 2014 Annual Results

For the year ended 31 December, 2014, Sino Biopharm recorded the following operational results:

 

Turnover was approximately HK$12,378.35 million, an increase of approximately 25% over the same period last year;

 

Before and after accounted for unrealized fair value (gains)/losses of equity investments at fair value through profit or loss, profit attributable to the Group was approximately HK$1,477.53 million and approximately HK$1,513.21 million, respectively, approximately 38.7% and approximately 46% higher than the same period last year, respectively;

 

Based on the profit attributable to Sino Biopharm before and after accounted for unrealized fair value (gains)/losses of equity investments at fair value through profit or loss, the basic earnings per share were approximately HK29.90 cents and approximately HK30.62 cents, respectively, approximately 38.7% and approximately 45.9% higher than the same period last year, respectively;

 

Sales of new products accounted for approximately 26.2% of Sino Biopharm total revenue; and Cash and bank balances as at 31 December, 2014 was approximately HK$4,468.33 million.

 

The Board of Directors (the “Directors”) of the Company recommended a final dividend payment of HK1.5 cents per share for the year ended 31 December, 2014. Together with the quarterly dividend of HK4.5 cents per share paid for the first three quarters, the total dividend of the whole year amounted to HK6 cents per share.

 

2545265631.pdf (138KB, PDF)